期刊文献+

S100P、GATA3、Ki-67在膀胱尿路上皮癌中的表达及意义 被引量:3

Expression and Significance of S100P,GATA3,and Ki-67 in bladder urothelial carcinoma
下载PDF
导出
摘要 目的:探讨S100P、GATA3、Ki-67在膀胱尿路上皮癌中的表达及意义。方法回顾性分析本院收治的2011年1月~2013年12月56例膀胱尿路上皮癌和32例尿路上皮增生患者的临床资料,应用免疫组织化学SP法检测56例膀胱尿路上皮癌和32例尿路上皮增生中S100P、GATA3、Ki-67的表达水平。结果 S100P、GATA3、Ki-67在膀胱尿路上皮癌中呈中至强阳性表达,在低级别非浸润性膀胱尿路上皮癌阳性表达率分别为90.0%、87.5%、85.0%,在高级别浸润性膀胱尿路上皮癌阳性表达率分别为93.8%、87.5%、100.0%;在尿路上皮增生中阳性表达率分别为3.1%、6.2%、6.2%。结论 S100P、GATA3、Ki-67在膀胱尿路上皮癌与尿路上皮增生的鉴别诊断中具有重要价值。 Objective To explore the expression and significance of S100P,GATA3,and Ki-67 in bladder urothelial carcinoma. Methods Clinical data from 56 cases with bladder urothelial carcinoma and 32 cases with urothelial hyper-plasia treated in our hospital from January 2011 to December 2013 were retrospectively analyzed.Expression level of S100P,GATA3,and Ki-67 in 56 bladder urothelial carcinoma cases and 32 urothelial hyperplasia cases were deter-mined by immunohistochemistry SP method. Results S100P,GATA3,and Ki-67 had moderate and strong positive ex-pression in bladder urothelial carcinoma.Positive expression rate of the three indexes in low grade and non-invasive urothelium carcinoma was 90.0%,87.5%,and 85.0% respectively.In the high grade and invasive urothelium carcinoma,it was 93.8%,87.5%,and 100.0% respectively.In the urothelial hyperplasia,positive expression rate of these three deter-mined indexes in urothelial hyperplasia was 3.1%,6.2%,and 6.2% respectively. Conclusion S100P,GATA3,and Ki-67 has important value in the differential diagnosis between bladder urothelial carcinoma and urothelial hyperplasia.
出处 《中国当代医药》 2015年第12期13-16,29,共5页 China Modern Medicine
关键词 膀胱尿路上皮癌 S100P GATA3 KI-67 免疫组织化学 Bladder urothelial carcinoma S100P GATA3 Ki-67 Immunohistochemistry
  • 相关文献

参考文献19

  • 1朱娟娟,曾芸(综述),杨宝学(审校).膀胱癌相关因子研究进展[J].中国肿瘤临床,2013,40(12):741-744. 被引量:6
  • 2Jemal A, Bray F,Center MM,et al.Global cancer statistics [J].CA Cancer J Clin, 2011,61 (2) : 69-90.
  • 3张涛,陈如,马锋.肌层浸润性膀胱癌化疗研究进展[J].山东医药,2013,53(40):88-90. 被引量:6
  • 4Beesley MF,Mclaren KM.Cytokeratinl9 and galectin-3 im- munohistochemistry in the differential diagnosis of solitary thyroid nodules[J].Histopathology, 2002,81 (2) : 236-243.
  • 5Higgins JP,Kaygusuz G,Wang L,et al.Placental S100(S 100P) and GATA3:markers for transitional epithelium and urothe- lial carcinoma discovered by complementary DNA mi- eroarray[J].Am J Surg Pathol, 2007,31 (5) : 673-680.
  • 6Becket T,Gerke V,Kuhe E,et al.S10OP,a novel Ca^2+-bind- ing protein from human placenta.eDNA cloning,recombi- nant protein expression and Ca^2+ binding properties[J].Eur J Bioehem, 1992,207(2):541-547.
  • 7Parkkila S,Pan PW,Ward A,et al.The calcium-binding protein SLOOP in normal and malignant human tissues[J]. BMC Clin Pathol, 2008 ; 8: 2.
  • 8谢宇,杨罗艳,江勃年,谭春祈,周晓.S100P在膀胱移行细胞癌中的表达与意义[J].医学临床研究,2009,26(9):1651-1652. 被引量:3
  • 9崔天庆,李云霞.钙结合蛋白S100P在肿瘤中的研究进展[J].医学综述,2014,20(8):1368-1370. 被引量:7
  • 10Zheng W, Flavell RA.The transcription factor GATA-3 is necessary and sufficient for Th2 eytokine gene expres- sion in CD4 T cells[J].Cell, 1997,89(4) :587-596.

二级参考文献102

  • 1李鸣,李宁忱,黄真,那彦群.浸润性膀胱癌术前选择性髂内动脉灌注化疗的近远期疗效观察[J].中华泌尿外科杂志,2004,25(10):662-664. 被引量:20
  • 2侯建国,杨波,孙颖浩,万蓬.浸润性膀胱癌患者的保留膀胱综合治疗[J].临床泌尿外科杂志,2004,19(10):619-620. 被引量:12
  • 3王莉,刘风花,刘若男.新辅助化疗对宫颈鳞癌细胞增殖与凋亡的影响[J].第三军医大学学报,2005,27(15):1599-1600. 被引量:1
  • 4李永红,刘卓炜,周芳坚,秦自科,韩辉,余绍龙.保留膀胱手术联合动脉化疗治疗浸润性膀胱癌的临床研究[J].癌症进展,2007,5(2):127-130. 被引量:6
  • 5Parkin M D, Bray F, Ferlay J, et al. Global Cancer Statistics,2002 [J]. CA CancerJClin, 2005, 55(2): 74-108.
  • 6Stein J P, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invaslve bladder cancer: long-term results in 1054 patients [J]. JClin Oncol, 2001, 19(3): 666 -675.
  • 7Stein J P, Quek M L, Skinner D G. Lymphadenectomy for invasive bladder cancer: I. historical perspective and contemporary rationale [J]. BJUInt, 2006, 97(2): 227-231.
  • 8Nieuwenhuijzen J A, Bex A, Meinhardt W, et al. Neocadjuvant roethotrex- ate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer[J]. J Urol, 2005, 174(1) : 80-85.
  • 9Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration [ J]. Eur Urol, 2005, 48 ( 2 ) : 202 - 205.
  • 10Diestra J E, Condom E, Del-Muro X G, et al. Expression of multidrug resistance proteins P-glycoprotein, muhidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications[J]. J Urol, 2003, 170(4 Pt 1) : 1383 - 1387.

共引文献78

同被引文献15

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部